SEC Form 4 · accession 0001144204-17-063296
OPIANT PHARMACEUTICALS, INC. · OPNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geoffrey Wolf
10% Owner
Period of report
Dec 1, 2017
Accepted (ET)
Dec 12, 2017 · 2:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385508
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.001 par value per shareF1 | Dec 1, 2017 | C | 30,000 | $15.00 | A | 30,000 | D | |
| Common Stock, $.001 par value per share | Dec 7, 2017 | C | 17,718 | $15.00 | A | 47,718 | D | |
| Common Stock, $.001 par value per share | Dec 7, 2017 | C | 62,656 | $5.00 | A | 110,374 | D | |
| Common Stock, $.001 par value per share | Dec 8, 2017 | S | 2,570 | $30.40 | D | 107,804 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantsF2 | $15.00 | Dec 1, 2017 | C | 30,000 | D | Sep 1, 2017 | Dec 31, 2017 | Common Stock | 30,000 | 315,000 | D |
| OptionsF2 | $15.00 | Dec 7, 2017 | C | 35,000 | D | Sep 1, 2017 | Dec 31, 2017 | Common Stock | 17,718 | 0 | D |
| OptionsF3 | $5.00 | Dec 7, 2017 | C | 75,000 | D | — | Jun 14, 2024 | Common Stock | 62,656 | 0 | D |
Explanation of responses
- F1This Form 4 is a late filing reporting the changes in beneficial ownership of the Reporting Person as of December 11, 2017. This Form 4 was required to be filed within two business days of 12/01/2017, the date the Reporting Person acquired shares.
- F2These Warrants and Options could only be exercised between the following dates: (i) the earliest date on which the price per Share has traded at or above US$ 30.00 for at least three (3) trading days out of any ten (10) consecutive trading days; and (ii) the Expiration Date (December 31, 2017). These Warrants and Options became exercisable on September 1, 2017.
- F3These options could only be exercised between the following dates: (i) the first to occur of: (A) the commencement of the next trial with respect to the opioid overdose reversal treatment; (B) the entrance into a distribution, licensing, royalty, partnership, collaboration or other significant transaction with respect to the opioid overdose reversal treatment; or (C) the filing of a New Drug Application with the U.S. Food and Drug Administration with respect to the opioid overdose reversal treatment; and (ii) the Expiration Date (June 14, 2024).